MedTrace Logo

Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis

NCT02063399 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20302

Last updated 2022-10-17

No results posted yet for this study

Summary

The purpose of this study is to determine if the screening of nasopharyngeal carcinoma using plasma Epstein-Barr virus DNA analysis would result in the detecting NPC cases at earlier stages and improve survival.

Conditions

  • Nasopharyngeal Carcinoma

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Kwan-chee Allen Chan, MD, PhD · Chinese University of Hong Kong

Eligibility

Min Age
40 Years
Max Age
62 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-08-31
Completion
2023-06-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02063399 on ClinicalTrials.gov